Transparency Notification

Transparency Notification




Transparency Notification

THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.

PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION

(ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE OF MAJOR HOLDINGS)

Acacia Pharma Group plc

 1.     Summary of the notification

Cambridge, UK and Indianapolis, US – 05 March 2021, 09:00 CET: Acacia Pharma Group plc has received a transparency notification dated 02 March 2021 indicating that Coltrane Asset Management L.P. now holds, by virtue of the purchase of shares on 18 February 2021, 5.50% of the voting rights of the company. Coltrane has therefore crossed the threshold of 5%.

2.     Content of notification
The notification dated 2 March 2021 contains the following information:

  • Reason of the notification – acquisition or disposal of voting securities or voting rights
  • Notification by – a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
Name Address (for legal entities)
Mandeep Manku 250 W 55th St 16C
New York, NY 10019
Coltrane Asset Management Holdings, Ltd 94 Solaris Avenue
Camana Bay, Grand Cayman KY1-1108, Cayman Islands
Coltrane Asset Management, L.P. 94 Solaris Avenue
Camana Bay, Grand Cayman KY1-1108, Cayman Islands
  • Date on which the threshold is crossed – 18 February 2021
  • Threshold that is crossed – 5%
  • Denominator – 89,689,451
  • Notified details:
A)     Voting rights Previous notification After the transaction
  # of voting rights # of voting rights % of voting rights
Holders of voting rights   Linked to securities Not linked to securities Linked to securities Not linked to securities
Mandeep Manku   0 0 0.00% 0.00%
Coltrane Asset Management, L.P.   4,931,684 0 5.50% 0.00%
Subtotal   4,931,684   5.50%  
  TOTAL 4,931,684 0 5.50% 0.00%

B)     Voting rights After the transaction
Holders of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement
             
  TOTAL     0 0.00%  
             
  TOTAL (A+B)     # of voting rights % of voting rights  
      CALCULATE 4,931,684 5.50%  

Full chain of controlled undertakings through which the holding is effectively held:

  • Coltrane Asset Management, L.P. is an investment advisor which manages funds and accounts which hold the shares reported in this filing.
  • Coltrane Asset Management, L.P. can exercise the voting rights at its discretion, without any instruction from its clients.
  • Coltrane Asset Management, L.P. is controlled by Coltrane Asset Management Holdings, Ltd, which is controlled by Mandeep Manku.

             

  1. Miscellaneous

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com

 

International Media
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com
US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com
Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be

Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma’s first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

www.acaciapharma.com

Attachment